Mechanisms of Tumor Necrosis Factor α Antagonist-Induced Lupus in a Murine Model

被引:18
|
作者
Xu, Yuan [1 ]
Zhuang, Haoyang [1 ]
Han, Shuhong [1 ]
Liu, Chao [1 ]
Wang, Hai [1 ]
Mathews, Clayton E. [1 ]
Massini, John [1 ]
Yang, Lijun [1 ]
Reeves, Westley H. [1 ]
机构
[1] Univ Florida, Gainesville, FL 32610 USA
关键词
PLASMACYTOID DENDRITIC CELLS; ECTOPIC LYMPHOID-TISSUE; I INTERFERON; TNF-ALPHA; AUTOIMMUNE-DISEASES; AUTOANTIBODY PRODUCTION; SOMATIC HYPERMUTATION; RHEUMATOID-ARTHRITIS; GERMINAL-CENTERS; DEFICIENT MICE;
D O I
10.1002/art.38882
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. Tumor necrosis factor alpha (TNF alpha) antagonists are effective for treating rheumatoid arthritis and other inflammatory diseases, but their use can be complicated by the development of lupus-like phenomena. This study was undertaken to investigate the role of TNF alpha in a murine model of lupus. Methods. Toll-like receptor 7 (TLR-7) ligand-driven lupus was induced by injection of pristane into C57BL/6 (B6) mice deficient in TNF alpha (TNF alpha(-/-)) or TNF alpha-intact B6 mice as wild-type controls. Autoantibody and type I interferon (IFN) production was measured in each group of mice, and the effects of the presence or absence of TNF alpha on type I IFN-producing plasmacytoid dendritic cells (PDCs), Ly-6C(high) monocytes, and TNF alpha-producing neutrophils were determined. Results. TNF alpha(-/-) mice did not spontaneously develop autoantibodies or clinical manifestations of lupus, suggesting that TNF alpha deficiency alone is insufficient to cause lupus. Although the levels of type I IFN were comparable between untreated TNF alpha(-/-) and wildtype control mice, untreated TNF alpha(-/-) mice had increased circulating levels of PDCs and PDC-like cells, which enhanced the potential for production of type I IFN. When treated with pristane, TNF alpha(-/-) mice developed more severe lupus compared to pristane-treated controls, characterized by increased levels of anti-Sm/RNP autoantibodies, type I IFN, PDCs, and peritoneal inflammatory (Ly-6C(high)) monocytes. In pristane-treated TNF alpha(-/-) mice, the numbers of neutrophils, a cell type that promotes resolution of inflammation, were decreased considerably, whereas the responses of inflammatory monocytes and PDCs and the production of type I IFN were increased and prolonged. Conclusion. Low levels of TNF alpha will increase the number of circulating PDCs in mice, thereby enhancing the potential to produce type I IFN. However, this does not necessarily lead to type I IFN production or auto-immunity unless there is concomitant exposure to endogenous TLR-7 ligands, which are released from dead cells following pristane treatment. In humans, the rate of clearance of dead cells, along with the levels of TNF alpha, may influence who will develop lupus following treatment with TNF alpha inhibitors.
引用
收藏
页码:225 / 237
页数:13
相关论文
共 50 条
  • [41] MECHANISMS OF TUMOR-NECROSIS-FACTOR ACTION
    SCHUTZE, S
    MACHLEIDT, T
    KRONKE, M
    SEMINARS IN ONCOLOGY, 1992, 19 (02) : 16 - 24
  • [42] Green tea polyphenols block endotoxin-induced tumor necrosis factor-production and lethality in a murine model
    Yang, FJ
    de Villers, WJS
    McClain, CJ
    Varilek, GW
    JOURNAL OF NUTRITION, 1998, 128 (12): : 2334 - 2340
  • [43] Antiinflammatory Effects of Tumor Necrosis Factor on Hematopoietic Cells in a Murine Model of Erosive Arthritis
    Blueml, Stephan
    Binder, Nikolaus B.
    Niederreiter, Birgit
    Polzer, Karin
    Hayer, Silvia
    Tauber, Stefanie
    Schett, Georg
    Scheinecker, Clemens
    Kollias, George
    Selzer, Edgar
    Bilban, Martin
    Smolen, Josef S.
    Superti-Furga, Giulio
    Redlich, Kurt
    ARTHRITIS AND RHEUMATISM, 2010, 62 (06): : 1608 - 1619
  • [44] Regulation of matrix metalloproteinase expression by tumor necrosis factor in a murine model of retinal neovascularization
    Majka, S
    McGuire, PG
    Das, A
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2002, 43 (01) : 260 - 266
  • [46] "Paradoxical joint inflammation" possibly induced by a tumor necrosis factor antagonist in three patients with psoriasis
    Di Costanzo, Luisa
    Ferrucci, Maria G.
    Cusano, Francesco
    GIORNALE ITALIANO DI DERMATOLOGIA E VENEREOLOGIA, 2020, 155 (03): : 370 - 371
  • [47] Eczema-like reactions induced by tumor necrosis factor-alfa antagonist agents
    Pilar Arevalo, Maria
    Fonseca, Eduardo
    Victoria Nespereira, Maria
    Maria Fernandez-Torres, Rosa
    Paradela, Sabela
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2013, 68 (04) : AB180 - AB180
  • [48] TREATMENT OF A MURINE MAMMARY-TUMOR WITH THE TUMOR-NECROSIS-FACTOR
    JASNIS, MA
    KLEIN, D
    DELUSTIG, ES
    MEDICINA-BUENOS AIRES, 1987, 47 (06) : 624 - 624
  • [49] Quinine inhibits release of tumor necrosis factor, apoptosis, necrosis and mortality in a murine model of septic liver failure
    Gantner, F
    Uhlig, S
    Wendel, A
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1995, 294 (01) : 353 - 355
  • [50] Treatment of necrobiosis lipoidica with the tumor necrosis factor antagonist etanercept
    Zeichner, JA
    Stern, DWK
    Lebwohl, M
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2006, 54 (03) : S120 - S121